Document is current

Article History

Received: 29 October 2024

Accepted: 27 January 2025

First Online: 8 February 2025

Declarations

:

: Not applicable.

: Not applicable.

: This document was reviewed across the entire membership of the guideline group which is a joint committee of both the Association of British Clinical Diabetologist (ABCD) and UK Kidney Association (UKKA).AF has attended drug advisory boards of Boehringer Ingleheim, AstraZeneca, NAPP, Novo Nordisk, MSD, VP UK.PW has received honoraria for delivering educational meetings and/or attending advisory boards for Abbott, Astra Zeneca, Bayer, Boehringer Ingleheim, Eli Lilly, MSD, NAPP, Sanofi, Novo and Vifor Pharmaceuticals.SCB reported receiving personal fees from AstraZeneca, Boehringer Ingelheim, Eli Lilly, Merck Sharp & Dohme, Novo Nordisk and Sanofi-Aventis (honoraria); Medscape (funding for the development of educational programmes); All Wales Medicines Strategy Group and National Institute for Health and Care Excellence UK (providing expert advice) and is a shareholder of Glycosmedia.SB has received speaker fees and support to attend educational meetings from AstraZeneca, Novo Nordisk, Eli Lilly and Boehringer Ingelheim.PD has received honoraria for educational meetings from AstraZeneca, Janssen, Boehringer Ingelheim, Novo, Sanofi, Novartis, Abbott, MSD, Takeda, Roche, Lilly, Ascensia, BD, Internis, GSK, Menarini, Daichi-Sankyo, Bayer and Besins.DB has received grant from AstraZeneca and speaker fees from Vifor Pharma.JK has received honoraria for delivering educational meetings and/or attending advisory boards from Boehringer Ingelheim, AstraZeneca, Sanofi, NAPP and research grants from AstraZeneca and Sanofi.ID is chief investigator in the UK for three GSK sponsored trials and has chaired GSK advisory board. He has received a research grant from Sanofi Genzyme.Other authors have declared no competing interests.

: Not applicable.